Drug price hikes in Germany could cost health insurers extra $6.2 billion annually, study finds

What happened

A Harvard Medical School study estimates Germany’s statutory health insurers would face $6.2 billion in extra annual costs if Germany raised drug prices by 25% in response to US pressure. The study estimates US Medicaid spending would rise by $301 million annually, far less than the German increase.

Confirmed

Global impact / market context

If German drug prices rise, insurers could pay more for prescriptions, increasing pressure on their budgets and potentially on contributions or public funding. The study suggests this would not simply transfer costs from the US, because US Medicaid spending would also rise, though by much less.

Analyst inference

The estimate concerns a 25% German price increase, not a reported policy change. The US policy described seeks to link some medicine prices to those in reference countries, including Germany; the study’s figures show how a response could raise spending in both countries.

Confirmed

What to watch

1. Watch for any German decision to raise medicine prices in response to US pressure; the article describes the increase as a scenario, not an enacted change. Analyst inference
2. Check whether the US expands its reference-country pricing policy, which links some US medicine prices to prices in other wealthy countries. Analyst inference
3. Track whether insurers or policymakers cite the study’s cost estimates in discussions of drug pricing, as the German insurers’ association says the findings support its position. Confirmed

Evidence

• Original source link unavailable